Ovarian cancer screening: Difference between revisions
Jump to navigation
Jump to search
Hudakarman (talk | contribs) No edit summary |
No edit summary |
||
| (8 intermediate revisions by 2 users not shown) | |||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Ovarian cancer}} | |||
{{CMG}}; {{AE}} {{Hudakarman}} | |||
==Overview== | |||
There are no recommendations for [[screening]] [[ovarian cancer]] in asymptomatic women although better outcome is associated with early [[diagnosis]]. [[Biomarkers]] from [[peritoneal fluid]] can be used as a mean of early detection of [[ovarian cancer]] but this is still an emerging proof. Examples of [[screening]] and [[diagnostic]] methods for [[ovarian cancer]] include [[pelvic examination]], [[CA125|cancer antigen 125]] ([[CA125]]) [[tumor marker]], [[transvaginal ultrasound]] (TVU), multimarker panels, and bioinformatic analysis of proteomic patterns. | |||
*There are no recommendations for [[screening]] [[ovarian cancer]] in asymptomatic women although better outcome is associated with early [[diagnosis]]<ref name="pmid27284942">{{cite journal| author=Galea M, Gauci G, Calleja-Agius J, Schembri-Wismayer P| title=Peritoneal biomarkers in the early detection of ovarian cancer. | journal=Minerva Ginecol | year= 2017 | volume= 69 | issue= 1 | pages= 84-99 | pmid=27284942 | doi=10.23736/S0026-4784.16.03943-5 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=27284942 }} </ref> | ==Screening== | ||
*There are no recommendations for [[screening]] [[ovarian cancer]] in asymptomatic women although better outcome is associated with early [[diagnosis]].<ref name="pmid28170086">{{cite journal| author=Smith RA, Andrews KS, Brooks D, Fedewa SA, Manassaram-Baptiste D, Saslow D et al.| title=Cancer screening in the United States, 2017: A review of current American Cancer Society guidelines and current issues in cancer screening. | journal=CA Cancer J Clin | year= 2017 | volume= 67 | issue= 2 | pages= 100-121 | pmid=28170086 | doi=10.3322/caac.21392 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=28170086 }} </ref><ref name="pmid27284942">{{cite journal| author=Galea M, Gauci G, Calleja-Agius J, Schembri-Wismayer P| title=Peritoneal biomarkers in the early detection of ovarian cancer. | journal=Minerva Ginecol | year= 2017 | volume= 69 | issue= 1 | pages= 84-99 | pmid=27284942 | doi=10.23736/S0026-4784.16.03943-5 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=27284942 }} </ref> | |||
*[[Ovarian cancer]] is the fifth most common cause of cancer-related [[mortality]] in women | *[[Ovarian cancer]] is the fifth most common cause of cancer-related [[mortality]] in women | ||
*75% of women with [[ovarian cancer]] are diagnosed in an advanced stage | *75% of women with [[ovarian cancer]] are diagnosed in an advanced stage | ||
*[[Ovarian cancer]] is the most [[lethal]] [[gynecological]] [[cancer]] | *[[Ovarian cancer]] is the most [[lethal]] [[gynecological]] [[cancer]] | ||
*The reason of increased [[mortality]] and late detection of [[ovarian cancer]] in its advanced stage is because the [[screening]] systems that are being used have poor or limited [[sensitivity]] and [[specificity]] | *The reason of increased [[mortality]] and late detection of [[ovarian cancer]] in its advanced stage is because the [[screening]] systems that are being used have poor or limited [[sensitivity]] and [[specificity]]. | ||
*[[Biomarkers]] from [[peritoneal fluid]] can be used as a mean of ealy detection of [[ovarian cancer]] but this is | *[[Biomarkers]] from [[peritoneal fluid]] can be used as a mean of ealy detection of [[ovarian cancer]] but this is still an emerging proof. | ||
*Examples of [[screening]] and [[diagnostic]] methods for [[ovarian cancer]] include: | *Examples of [[screening]] and [[diagnostic]] methods for [[ovarian cancer]] include:<ref>{{cite journal|doi=10.1158/1940-6207.CAPR-11-0378.}}</ref> | ||
**[[Pelvic examination]] | **[[Pelvic examination]] | ||
**[[Cancer antigen 125]] ([[CA 125]]) [[tumor marker]] | **[[Cancer antigen 125]] ([[CA 125]]) [[tumor marker]] | ||
**[[Transvaginal ultrasound]] ([[TVU]]) | **[[Transvaginal ultrasound]] ([[TVU]]) | ||
**Multimarker panels and bioinformatic analysis of proteomic patterns | **Multimarker panels and bioinformatic analysis of proteomic patterns | ||
*The [[UK Collaborative Trial of Ovarian Cancer Screening]] ([[UKCTOCS]])is evaluating a multimodal [[screening]] [[strategy]] ([[MMS]]) [[efficacy]] which consists of: | *The [[UK Collaborative Trial of Ovarian Cancer Screening]] ([[UKCTOCS]])is evaluating a multimodal [[screening]] [[strategy]] ([[MMS]]) [[efficacy]] which consists of: | ||
**Annual [[CA125]] screening, risk of [[ovarian cancer]] algorithm ([[ROCA]]), TVU | **Annual [[CA125]] screening, risk of [[ovarian cancer]] algorithm ([[ROCA]]), TVU | ||
*Patients with family history of [[ovarian cancer]] or [[breast cancer]] can have [[ovarian cancer hereditary syndrome]] as [[breast-ovarian cancer syndrome]] which is associated with | *Patients with family history of [[ovarian cancer]] or [[breast cancer]] can have [[ovarian cancer hereditary syndrome]] as [[breast-ovarian cancer syndrome]] which is associated with | ||
**[[BRCA1]] and [[BRCA2]] [[gene mutations]] | **[[BRCA1]] and [[BRCA2]] [[gene mutations]] | ||
**[[Lynch II syndrome]] | **[[Lynch II syndrome]] | ||
*Should undergo the following [[screening]]: | *Should undergo the following [[screening]]: | ||
**[[Annual]] | **[[Annual]] rectovaginal pelvic examinations | ||
**[[ | **[[CA125]] | ||
**[[TVU]] until completing | **[[Transvaginal ultrasound|TVU]] until completing childbearing or until age 35 years at least, where at this point [[prophylactic]] [[bilateral]] [[oophorectomy]] is recommended | ||
== References == | == References == | ||
{{reflist|2}} | {{reflist|2}} | ||
Latest revision as of 19:21, 14 October 2019
|
Ovarian cancer Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Ovarian cancer screening On the Web |
|
American Roentgen Ray Society Images of Ovarian cancer screening |
|
Risk calculators and risk factors for Ovarian cancer screening |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Huda A. Karman, M.D.
Overview
There are no recommendations for screening ovarian cancer in asymptomatic women although better outcome is associated with early diagnosis. Biomarkers from peritoneal fluid can be used as a mean of early detection of ovarian cancer but this is still an emerging proof. Examples of screening and diagnostic methods for ovarian cancer include pelvic examination, cancer antigen 125 (CA125) tumor marker, transvaginal ultrasound (TVU), multimarker panels, and bioinformatic analysis of proteomic patterns.
Screening
- There are no recommendations for screening ovarian cancer in asymptomatic women although better outcome is associated with early diagnosis.[1][2]
- Ovarian cancer is the fifth most common cause of cancer-related mortality in women
- 75% of women with ovarian cancer are diagnosed in an advanced stage
- Ovarian cancer is the most lethal gynecological cancer
- The reason of increased mortality and late detection of ovarian cancer in its advanced stage is because the screening systems that are being used have poor or limited sensitivity and specificity.
- Biomarkers from peritoneal fluid can be used as a mean of ealy detection of ovarian cancer but this is still an emerging proof.
- Examples of screening and diagnostic methods for ovarian cancer include:[3]
- Pelvic examination
- Cancer antigen 125 (CA 125) tumor marker
- Transvaginal ultrasound (TVU)
- Multimarker panels and bioinformatic analysis of proteomic patterns
- The UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS)is evaluating a multimodal screening strategy (MMS) efficacy which consists of:
- Annual CA125 screening, risk of ovarian cancer algorithm (ROCA), TVU
- Patients with family history of ovarian cancer or breast cancer can have ovarian cancer hereditary syndrome as breast-ovarian cancer syndrome which is associated with
- Should undergo the following screening:
- Annual rectovaginal pelvic examinations
- CA125
- TVU until completing childbearing or until age 35 years at least, where at this point prophylactic bilateral oophorectomy is recommended
References
- ↑ Smith RA, Andrews KS, Brooks D, Fedewa SA, Manassaram-Baptiste D, Saslow D; et al. (2017). "Cancer screening in the United States, 2017: A review of current American Cancer Society guidelines and current issues in cancer screening". CA Cancer J Clin. 67 (2): 100–121. doi:10.3322/caac.21392. PMID 28170086.
- ↑ Galea M, Gauci G, Calleja-Agius J, Schembri-Wismayer P (2017). "Peritoneal biomarkers in the early detection of ovarian cancer". Minerva Ginecol. 69 (1): 84–99. doi:10.23736/S0026-4784.16.03943-5. PMID 27284942.
- ↑ . doi:10.1158/1940-6207.CAPR-11-0378. Check
|doi=value (help). Missing or empty|title=(help)